SCHEMBL4720231

SCHEMBL4720231

CCOc1ccccc1-c1[c]nccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
TTR P02766 1/20 0.42
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 2/20 0.41
PPARG P37231 1/20 0.41
STAT3 P40763 1/20 0.41
NCOA2 Q15596 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
PTPRC P08575 1/20 0.40
GCGR P47871 1/20 0.39
MAPK14 Q16539 1/20 0.39
GUSB P08236 1/20 0.39
HPGD P15428 3/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRM5 P41594 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720650 0.88 PDE5A (0.45) PDE5AALDH1A1KDM4EGCGRMAPK14
SCHEMBL4723803 0.86 CYP1A2 (0.52) PDE5AKDM4EGCGRMAPK14
SCHEMBL4720896 0.83 CCNB2 (0.44) PDE5AALDH1A1KDM4EHPGDTDP1
SCHEMBL4765574 0.77 PDE5A (0.46) PDE5ANPSR1TTRALDH1A1KDM4E
SCHEMBL198911 0.74 ALDH1A1 (0.60) PDE5ANPSR1TTRALDH1A1KDM4E
SCHEMBL22261801 0.74 NPC1 (0.38) ALDH1A1MAPK14HPGDTSHRHSD17B10
SCHEMBL28185277 0.72 PDE5A (0.53) PDE5ANPSR1TTRALDH1A1KDM4E
SCHEMBL22261800 0.70 NOTUM (0.38) ALDH1A1KDM4E
SCHEMBL4721743 0.70 PDE5A (0.42) PDE5ANPSR1TTRALDH1A1KDM4E
SCHEMBL4722123 0.70 PDE5A (0.42) PDE5ANPSR1TTRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 PDE5A 269/4885NPSR1 367/4885TTR 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.